Medical Oncology

, Volume 29, Issue 4, pp 2586–2593

Role of HER2-neu as a prognostic factor for survival and relapse in pT1a–bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis

Review Article

DOI: 10.1007/s12032-012-0201-4

Cite this article as:
Petrelli, F. & Barni, S. Med Oncol (2012) 29: 2586. doi:10.1007/s12032-012-0201-4


High levels of human epidermal growth receptor 2 (HER2) expression are associated with recurrence and death in breast cancer (BC) patients. We have performed a systematic review and meta-analysis in order to evaluate the prognosis for HER2+ pT1a–bN0M0 BC patients. A search of PubMed and Embase was performed. Studies were included if they reported hazard ratios (HRs) with a 95% confidence interval (CI) for multivariate analyses of relapse or survival in pT1a–bN0M0, HER2+ BC patients treated with surgery and chemotherapy and/or endocrine therapy, but not with trastuzumab. A total of 764 patients from seven studies were included in the meta-analysis. In the pooled analysis, HER2 had a detrimental effect on relapse-free (HR 4.68, 95% CI 3.05–7.18; p < 0.00001) and distant relapse-free survival, with a HR of 5.6 (95% CI 2.65–11.85; p < 0.00001). HER2+ status was also linked to increased risk of death (HR 3.4, 95% CI 0.86–13.41; p = 0.08) and worst BC-specific survival (HR 2.61, 95% CI 1.51–4.51; p = 0.0006), but these data were presented in few studies. HER2+ pT1a–bN0M0 BC is associated with a dismal prognosis. In these patients, HER2 has to be taken into account when deciding on adjuvant therapy, and trastuzumab should be considered.


pT1a–bN0M0HER2 positiveBreast cancerRelapseSurvivalPrognosis

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Medical Oncology Unit, Oncology DepartmentAzienda Ospedaliera Treviglio-CaravaggioTreviglioItaly